The Top 20 Best-Selling Drugs Globally in Q1 2024

The pharmaceutical industry has continued to evolve, with the landscape shifting as new treatments emerge and existing drugs see changing fortunes. According to the latest data, the top 20 best-selling drugs globally in the first quarter of 2024 generated over $50 billion in sales, representing a 14% increase compared to the same period in 2023.

The data reveals several key trends. Biologics now account for half of the top-selling drugs, underscoring the growing prominence of this drug class. Oncology, autoimmune diseases, and chronic conditions remain the three hottest therapeutic areas, collectively making up 9 of the top 20 products.

Notably, the once-dominant Humira experienced a significant 36% year-over-year decline in sales due to patent expiration, falling to just $2.27 billion in Q1 2024. This shift has opened the door for other drugs to potentially surpass the $10 billion annual sales mark, with Darzalex, Trikafta, Gardasil, and Skyrizi all showing strong growth trajectories.

On the other end of the spectrum, Eylea, Opdivo, and Revlimid saw single-digit sales declines, bucking the overall trend of growth. However, the star performer was Eli Lilly's Mounjaro, which saw an astounding 218% surge in sales, underscoring the continued demand for innovative diabetes treatments.

As the industry landscape evolves, it will be fascinating to see which drugs are able to capitalize on emerging opportunities and cement their positions as the next generation of blockbusters. The race to join the $10 billion club is certainly heating up, with several contenders poised to make their mark in the coming year.